CTLA4 and Miyoshi myopathy: Specific polymorphisms, like the CTLA4 rs231775 AA/AG genotype, have been linked to poorer outcomes, which highlights the need to identify subgroups of MM patients who could potentially benefit from ICI therapies [13,16,17].